Effect of Dexmedetomidine on Propofol Requirement During Anesthesia
Status:
Completed
Trial end date:
2017-03-20
Target enrollment:
Participant gender:
Summary
Dexmedetomidine, a selective alpha-2 agonist agent used for maintaining sedation in intensive
care patients in receipt of mechanical ventilation, is being increasingly utilized in
anaesthesia practice for facilitating anaesthesia depth as an adjunct to base anaesthetics
(intravenous; propofol: inhalational; sevoflurane, desflurane). The investigators intend to
assess the anaesthetic potential of dexmedetomidine in controlled anaesthesia settings
empowered by the use of an objective, patient response based, safe, efficient, and patented
closed loop anaesthesia delivery system (CLADS). CLADS functions on control of processed EEG
response parameter captured from anaesthetized patients with the help of a BIS- monitor,
which is continuously fed into a automated drug infusion pump. The infusion pump then
accordingly delivers the anaesthetic drug to the patients based on pharmacodynamic
requirements. If dexmedetomidine has anaesthesia potential then it is likely that propofol
use delivered by CLADS can be reduced further. In addition the effect of two drugs (viz, base
agent-propofol plus adjunct agent-dexmedetomidine) on different receptor site within the
brain would help gain greater anaesthetic depth consistency as well as a lower incidence of
intraoperative patient awareness. This prospective randomized two-arm study aims to assess
effect of the use of dexmedetomidine on propofol requirements (primary objective),
anaesthesia depth consistency, and intraoperative patient awareness (secondary objectives).